The Hungarian pharmaceutical industry, marking its 35th anniversary under the umbrella of the National Association of Hungarian Pharmaceutical Manufacturers (Magyosz), continues to assert its significance within the national economy.

David Greskovits, president of Magyosz, emphasized that domestically produced medicines assure consumers of safety, innovation, and homegrown expertise.

Historically, the Hungarian pharmaceutical sector has navigated numerous challenges, including the impacts of wars, nationalization, privatization, and regime change.

This long-standing industry, allocated a strategic role in the COMECON system, has evolved into a vital economic sector with substantial export markets.

In recent years, the pharmaceutical landscape has been influenced by turbulent geopolitical and economic factors.

Although the industry has faced inflation, currency volatility, and supply chain disruptions, it maintains considerable national economic weight and provides employment for approximately 15,000 individuals.

The industry also contributes significantly to Hungary's manufacturing sector, delivering high added value per employee.

A key driver of competitiveness within the Hungarian pharmaceutical sector is its robust research and development potential.

Companies such as Richter invest strategically in R&D, with timeframes for studies extending up to 20 years.

Hungary has distinguished itself in intellectual property retention, reflected in a reported 14,000 active pharmaceutical patents as of 2023, underscoring the importance of innovation and research capacity.

Furthermore, the sector accounts for about 6.9% of the gross added value generated by Hungarian manufacturing, positioning it among the industry's leaders.

With an export figure placing Hungary as the 19th largest pharmaceutical exporter globally, and 12th on a per capita basis, 80% of production is directed to international markets, primarily in Europe and the United States.

The industry is increasingly harnessing digitalization and automation technologies, including artificial intelligence (AI), which enhance research efficiency and reduce costs.

While AI is mainly viewed as a tool to streamline administrative processes, Greskovits highlighted the continuous necessity of human input in pharmaceutical manufacturing.

Magyosz has raised concerns over the environmental impact of pharmaceutical waste, which has escalated due to low drug prices leading to overconsumption and wastefulness among consumers.

Greskovits noted the obligation for pharmaceutical manufacturers to manage disposal, generating significant financial burdens.

The pricing of pharmaceuticals has also come under scrutiny, particularly in light of legislative frameworks that have not seen price increases for prescription medications since 2006. Drug prices in Hungary are strictly regulated by the National Health Insurance Fund (NEAK), where manufacturers are required to continuously lower prices to remain within supported categories.

The lack of price increase has led some companies to withdraw products from support, impacting availability.

State support in the pharmaceutical sector has been low, generally around 4-5%, compared to 40-50% for other industries, resulting in competitive disadvantages.

Greskovits emphasized the detrimental effects of the recently abolished extra profit tax on exporters, with significant financial implications for domestic manufacturers.

The European Union introduced a pharmaceutical industry reform expected to favor domestically produced medicines within regulatory frameworks, which could yield positive outcomes for Hungarian manufacturers.

However, challenges remain, especially with new directives regarding wastewater treatment that could impose substantial financial responsibilities on the sector.

Marketing regulations in Hungary prohibit advertising for prescription drugs, contrasting with practices in other countries.

However, there are concerns regarding the influence of marketing on consumer behavior, particularly towards over-the-counter products.

The accuracy of information and diagnostics is pivotal for therapeutic decisions, with stringent controls ensuring that medications meet safety standards before reaching patients.

Despite ongoing pressures to reduce carbon footprints, industry stakeholders assert that environmental sustainability is essential for long-term competitiveness.

As they strive to balance production efficiency with ecological considerations, Hungarian pharmaceutical companies are also taking significant steps towards environmental certification.

In the context of Hungary's economic landscape, the pharmaceutical industry is often framed as a potential growth sector, contributing to broader economic resilience and advancement.